Breaking

Additional Strong Assays Results Extend High-Grade Antimony Mineralisation at Oaky Creek
Jeffrey Christian: Gold, Silver Prices to Rise, Risk Highest Since WWII
Uranium Market Facing Supply Crunch as Nuclear Fleet Grows
Crypto Market Update: Iran War Drives Oil Derivatives Boom on Crypto Exchange
Syntholene Selects Papadakis Engineering as Integration Partner for Novel Thermal-Hybrid Synthetic Fuel Demonstration Facility Heat Exchanger System
Silver Stocks: 5 Biggest Silver-mining Companies in 2026
Canada’s Junior Miners Still in Challenging Financial Climate as Metals Prices Climb
Benchmark: Surging Copper Prices Highlight Looming Global Supply Challenges

Investing
Economy
Latest News
Stock
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

Related Posts

Additional Strong Assays Results Extend High-Grade Antimony Mineralisation at Oaky Creek

Uranium Market Facing Supply Crunch as Nuclear Fleet Grows

Jeffrey Christian: Gold, Silver Prices to Rise, Risk Highest Since WWII

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Please enter CoinGecko Free Api Key to get this plugin works.

Disclaimer: BigCapitalTrend.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 bigcapitaltrend.com | All Rights Reserved

Top

Investing
Economy
Latest News
Stock

Type above and press Enter to search. Press Esc to cancel.